EIK1005-002: Et klinisk forskningsstudie, der evaluerer EIK1005, en Werner-helicase-hæmmer, som monoterapi og i kombination med pembrolizumab hos deltagere med avancerede solide tumorer inklusive tumorer med høj mikrosatellitinstabilitet (MSI-H)
Et multicenter, multi-delt, fase 1/2-studie af EIK1005 som monoterapi og i kombination med pembrolizumab hos deltagere med fremskredne solide tumorer, herunder checkpoint-hæmmende naïve deltagere med høj mikrosatellitinstabilitet (MSI-H) eller mismatch reparation defekte (dMMR) tumorer
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.
The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:
- Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
- Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
- Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Ana C Mamede, PharmD
- Telefonnummer: 347-806-4584
- E-mail: mamedea@eikontx.com
Undersøgelse Kontakt Backup
- Navn: Krishna Kaza
- E-mail: kazak@eikontx.com
Studiesteder
-
-
New South Wales
-
Saint Leonards, New South Wales, Australien
- Ikke rekrutterer endnu
- GenesisCare North Shore (Oncology)
-
Waratah, New South Wales, Australien
- Rekruttering
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Ballarat, Victoria, Australien
- Rekruttering
- Grampians Health
-
Camperdown, Victoria, Australien
- Rekruttering
- Chris O'Brien Lifehouse (Sydney Cancer Centre)
-
Frankston, Victoria, Australien
- Rekruttering
- Peninsula and Southeast Oncology (PASO) Medical
-
Frankston, Victoria, Australien, 3199
- Rekruttering
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
-
-
-
-
-
Brussels, Belgien, 1020
- Rekruttering
- Centre Hospitalier Universitaire Brugmann - Victor Horta
-
-
-
-
-
Kuopio, Finland, 70210
- Rekruttering
- Kuopio University Hospital
-
-
-
-
California
-
Los Angeles, California, Forenede Stater, 90027
- Rekruttering
- California Research Institute (CRI)
-
-
Florida
-
Doral, Florida, Forenede Stater, 33172
- Rekruttering
- Omnicure Clinical Research
-
Hialeah, Florida, Forenede Stater, 33013
- Rekruttering
- Bioresearch Partner
-
Plantation, Florida, Forenede Stater, 33322
- Rekruttering
- Florida Clinical Trials Group
-
Tamarac, Florida, Forenede Stater, 33321
- Rekruttering
- Florida Clinical Trials Group - Tamarac
-
-
New Jersey
-
Morristown, New Jersey, Forenede Stater, 07960
- Rekruttering
- Morristown Medical Center
-
-
New York
-
Lake Success, New York, Forenede Stater, 11042
- Rekruttering
- START New York-Long Island
-
New York, New York, Forenede Stater, 10022
- Rekruttering
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- START Dallas Fort Worth
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- University of Texas MD Anderson Cancer Center
-
-
-
-
Rhone
-
Pierre-Bénite, Rhone, Frankrig, 69310
- Rekruttering
- Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
-
-
-
-
-
Rome, Italien, 00128
- Rekruttering
- Campus Bio-Medico di Rome University
-
-
-
-
-
Wellington, New Zealand
- Rekruttering
- Health New Zealand
-
-
Manawatu
-
Roslyn, Manawatu, New Zealand, 4414
- Rekruttering
- Palmerstone North Hospital
-
-
-
-
-
Oslo, Norge, 0379
- Rekruttering
- Oslo University
-
-
-
-
-
Krakow, Polen, 31-864
- Rekruttering
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
Lodz, Polen, 90-338
- Rekruttering
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Polen, 70-419
- Rekruttering
- One Day Med
-
-
-
-
-
Lisbon, Portugal, 1649-028
- Rekruttering
- Hospital de Santa Maria
-
Loures, Portugal, 2674-514
- Rekruttering
- Unidade Local de Saúde (ULS) Loures Odivelas
-
Porto, Portugal, 4200
- Rekruttering
- Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
-
-
Lisbon District
-
Lisbon, Lisbon District, Portugal, 1500-650
- Rekruttering
- Hospital da Luz Lisboa
-
-
-
-
-
Singapore, Singapore, 119074
- Rekruttering
- National University Hospital (NUH)
-
-
Central Region
-
Singapore, Central Region, Singapore, 168583
- Rekruttering
- National Cancer Centre Singapore (NCCS)
-
-
-
-
-
Barcelona, Spanien, 08023
- Rekruttering
- START - Barcelona
-
Logroño, Spanien, 26006
- Rekruttering
- START Rioja - Hospital de San Pedro
-
Madrid, Spanien, 28233
- Rekruttering
- NEXT Madrid HUQSM
-
Zaragoza, Spanien, 50009
- Rekruttering
- Hospital Universitario Miguel Servet
-
-
Balearic Islands
-
Palma, Balearic Islands, Spanien, 07120
- Rekruttering
- Hospital Universitari Son Espases
-
-
Barcelona
-
Barcelona, Barcelona, Spanien, 8036
- Rekruttering
- Hospital Clinic Barcelona
-
-
-
-
-
Seoul, Sydkorea, 02841
- Rekruttering
- Korea University Anam Hospital
-
Suwon, Sydkorea, 16499
- Rekruttering
- Ajou University School of Medicine & Graduate School of Medicine
-
-
Busan
-
Busan, Busan, Sydkorea, 48108
- Rekruttering
- Inje University-Haeundae Paik Hospital
-
-
-
-
-
Berlin, Tyskland, 13125
- Rekruttering
- Helios Klinikum Berlin-Buch
-
Hamburg, Tyskland, 22297
- Rekruttering
- Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
-
-
Bavaria
-
Deggendorf, Bavaria, Tyskland, 94469
- Rekruttering
- DONAUISAR Klinikum
-
-
-
-
-
Linz, Østrig, 4020
- Rekruttering
- Ordensklinikum Linz Elisabethinen
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- is ≥ 18 years of age at the time of signing the informed consent.
- has a life expectancy of at least 3 months.
- has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
- In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
- has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
- has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
- has an adequate organ and marrow function.
Key Exclusion Criteria:
- has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
- has received prior treatment with Werner (WRN) inhibitor.
- has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
- In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- has known additional malignancy that is progressing or has required active treatment within the past 3 years.
- has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
- has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
- has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
- has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- has active tuberculosis.
- has any active infections requiring systemic therapy.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part 1A (Dose escalation, Monotherapy)
EIK1005 will be given as monotherapy in participants without alternative treatment options. |
EIK1005 is a selective inhibitor of the Werner helicase. |
|
Eksperimentel: Part 1B (Dose escalation, Combination with pembrolizumab)
EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors. |
EIK1005 is a selective inhibitor of the Werner helicase. Pembrolizumab is a PD-1 inhibitor. |
|
Eksperimentel: Part 2 (Dose optimization, Monotherapy)
Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A. |
EIK1005 is a selective inhibitor of the Werner helicase. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Dose-Limiting Toxicity (DLT) - Part 1
Tidsramme: 21 Days
|
A DLT is a protocol-defined adverse event occurring during the DLT observation period. |
21 Days
|
|
Adverse Events (AEs) - Part 1 and Part 2
Tidsramme: From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Number of participants reporting adverse events or serious adverse events. |
From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response (OR) - Part 1 and Part 2
Tidsramme: Through study completion, an average of 2 years.
|
OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Duration of Response (DOR) - Part 1 and Part 2
Tidsramme: Through study completion, an average of 2 years.
|
DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Disease Control (DC) - Part 1 and Part 2
Tidsramme: Through study completion, an average of 2 years.
|
DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Progression-free survival (PFS) - Part 2
Tidsramme: Through study completion, an average of 2 years.
|
PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first. |
Through study completion, an average of 2 years.
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Tidsramme: Up to 1 year
|
AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Tidsramme: Up to 1 year
|
AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Tidsramme: Up to 1 year
|
Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Tidsramme: Up to 1 year
|
tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Tidsramme: Up to 1 year
|
Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Studieleder: Nilou Mobashery, MD, Eikon Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Patologiske processer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Neoplastiske processer
- Genitale neoplasmer, kvindelige
- Uterine neoplasmer
- Patologiske tilstande, tegn og symptomer
- Neoplasma Metastase
- Endometriale neoplasmer
- Turcot syndrom
- pembrolizumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- EIK1005-002
- 2026-525248-13-00 (Ctis)
- KEYNOTE-G56 (Anden identifikator: Merck Sharp & Dohme LLC)
- MK-3475-G56 (Anden identifikator: Merck Sharp & Dohme LLC)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .